medigraphic.com
ISSN 1405-8871 (Print)

2026, Number 2

<< Back Next >>

Aten Fam 2026; 33 (2)

Irritant Contact Dermatitis Secondary to Capsaicin Use in an Oncology Patient

Mugno-Saba AM, Valencia-Cardenas LM, Cubillo-Duran EA

Language: Spanish
References: 11
Page: 117-119
PDF size: 137.80 Kb.


ABSTRACT

Capsaicin is a natural alkaloid derived from Capsicum peppers used transdermally as part of the therapeutic arsenal for neuropathic pain, particularly in second- or third-line treatment. Although its use is generally safe, local adverse effects such as burning and erythema are considered expected reactions. We present the case of a 64-year-old female with synchronous double malignancy (pancreatic carcinoma and colon adenocarcinoma), who developed grade 3 palmar-plantar neurotoxicity after eleven cycles of oxaliplatin. As part of symptomatic management, capsaicin patches were applied to both palms. Subsequently, the patient developed irritant contact dermatitis, identified as an adverse reaction to treatment.


REFERENCES

  1. Derry S, Rice ASC, Cole P, Tan T, Moore RA. Topicalcapsaicin (high concentration) for chronicneuropathic pain in adults. Cochrane DatabaseSyst Rev. 2017;1(1):CD007393.

  2. Jones VM, Moore KA, Peterson DM. Topical 8%capsaicin patch (Qutenza): a review of the evidence.J Pain Palliat Care Pharmacother. 2011;25(1):32-41.

  3. Petran EM, Periferakis A, Troumpata L, PeriferakisAT, Scheau AE, Badarau IA, et al. Capsaicin: EmergingPharmacological and Therapeutic Insights.Curr. Issues Mol. Biol. 2024;46(8):7895-7943.

  4. Petroianu GA, Aloum L, Adem A. Neuropathicpain: Mechanisms and therapeutic strategies. FrontCell Dev Biol. 2023;11:1072629.

  5. Teva Pharma. Ficha técnica Oxaliplatino [Internet].[Citado 2024 Oct 24]. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/69288/69288_ft.pdf

  6. Yang F, Zheng J. Understand spiciness: Mechanismof TRPV1 channel activation by capsaicin. ProteinCell. 2017;8(3):169–177.

  7. Sommer C, Cruccu G. Topical treatment of peripheralneuropathic pain: applying the evidence.J Pain Symptom Manage. 2016;53(3):614-629.

  8. Haanpää M, Cruccu G, Nurmikko TJ, McBrideWT, Docu A, Bosilkov A, et al. Capsaicin 8% patchversus oral pregabalin in patients with peripheralneuropathic pain. Eur J Pain. 2015;20(2):316-328.

  9. Moisset X. Neuropathic pain: Evidence based recommendations.Presse Med. 2024;53(2):104232.

  10. La Forgia M. Dermatitis irritativa por contacto.Dermatol Argent. 2012;18(3): 186-197.

  11. Grünenthal GmbH. Ficha técnica Qutenza parchecutáneo. CIMA AEMPS [Internet]. [Citado2024 Oct 24]. Disponible en: https://cima.aemps.es/cima/dochtml/ft/09524001/FichaTecnica_09524001.html#10




2020     |     www.medigraphic.com